GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Coya Therapeutics COYA · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.98

-3.56%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Coya Therapeutics — daily COYA Delayed
Market value
$69.9m
Last close × shares
Volume
71.1k
Shares, 19 Nov 2026

About Coya Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Coya Therapeutics is based in Houston, Texas and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker COYA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $7.9m and a net loss of $21.2m. At that date it held total assets of $50.0m and shareholders' equity of $43.0m.

In its own words

All references in this report to "Coya," the "Company," "we," "us," or "our" mean Coya Therapeutics, Inc. unless stated otherwise or the context otherwise indicates.

We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (“Tregs”). Tregs are a subpopulation of T-lymphocytes consisting of CD4+CD25high hFOXP3+ cells that suppress inflammatory responses. Tregs were first discovered in 1995 by Dr. Shimon Sakaguchi and since their discovery multiple lines of research have contributed to elucidate Treg biology and its role in health and disease. Dr. Sakaguchi was the 2025 winner of the Nobel Prize in Physiology or Medicine. Tregs and their transcription factors have been shown to be essential to maintaining cellular homeostasis by regulating autoimmune and inflammatory responses and maintaining self-tolerance in mammals. Dysfunctional Tregs underlie numerous disease states, and this cellular dysfunction is driven by the chronic inflammatory environment and high levels of oxidative stress commonly observed in certain diseases. Further, the degree of Treg dysfunction is correlated with the severity and progression of serious and life-threatening conditions. These and other recent advances in the understanding of Treg biology, have made this subset of T-lymphocytes an important potential therapeutic target, which we believe may provide new treatments for serious diseases.

Quoted from its 10-K, filed 16 Mar 2026. Read the filing on SEC.gov ↗

More about Coya Therapeutics →

Latest on Coya Therapeutics

Our reporting

Next results

15 Mar 2027

Due on 15 Mar 2027. Analysts expect earnings of -0.48 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Coya Therapeutics's ticker?

Coya Therapeutics trades as COYA on its US listing, under ISIN US22407B1089.

What was Coya Therapeutics's last closing price?

2.98 on 19 Nov 2026. The figure is in USD and is never converted.

When does Coya Therapeutics next report results?

Results are expected on 11 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.